Does Rallies show Form 4 insider transactions for OVID?

Yes. Rallies tracks OVID insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OVID research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OVID. It does not provide personalized investment advice.

OVID (Ovid Therapeutics Inc. Common Stock) Stock Analysis - Insider Trades

Ovid Therapeutics Inc. Common Stock (OVID) is a publicly traded Healthcare sector company. As of May 21, 2026, OVID trades at $2.36 with a market cap of $449.80M and a P/E ratio of 0.00. OVID moved -0.42% today. Year to date, OVID is +43.98%; over the trailing twelve months it is +724.71%. Its 52-week range spans $0.24 to $3.11. Analyst consensus is strong buy with an average price target of $5.33. Rallies surfaces OVID's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OVID stock inside the company?

Recent OVID insider activity includes ALEXANDER MARGARET A. sold 11.66K, Rona Jeffrey A sold 8.54K, ALEXANDER MARGARET A. sold 5.28K, Rona Jeffrey A sold 3.90K, and ALEXANDER MARGARET A. bought 6.81K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OVID Key Metrics

Key financial metrics for OVID
Metric	Value
Price	$2.36
Market Cap	$449.80M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$3.11
52-Week Low	$0.24
Volume	10
Avg Volume	0
Revenue (TTM)	$7.12M
Net Income	$-24.17M
Gross Margin	0.00%

Recent OVID Insider Trades

ALEXANDER MARGARET A. sold 11.66K (~$16.90K) on Feb 23, 2026.
Rona Jeffrey A sold 8.54K (~$12.38K) on Feb 23, 2026.
ALEXANDER MARGARET A. sold 5.28K (~$2.96K) on Feb 26, 2025.
Rona Jeffrey A sold 3.90K (~$2.19K) on Feb 26, 2025.
ALEXANDER MARGARET A. bought 6.81K (~$4.97K) on Jan 27, 2025.

Latest OVID News

Ovid Therapeutics Doses KCC2 Activator, Raises $60M PIPE, $53.9M Warrants, Ends Q1 with $165.6M — May 12, 2026
Ovid Therapeutics Tops Q4 Estimates with $0.06 EPS, Secures $81M Funding — Mar 18, 2026
Ovid Secures $60M Financing, Shows 7mg OV329 Safety and Clears OV4071 — Mar 18, 2026
Ovid Therapeutics Raises $60M Via Private Placement to Fund OV329 Expansion — Mar 18, 2026
Ovid Therapeutics to Present at Feb. 25, Mar. 4 and Mar. 11 Investor Conferences — Feb 25, 2026

OVID Analyst Consensus

8 analysts cover OVID: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.33.

Common questions about OVID

Who is trading OVID stock inside the company?: Recent OVID insider activity includes ALEXANDER MARGARET A. sold 11.66K, Rona Jeffrey A sold 8.54K, ALEXANDER MARGARET A. sold 5.28K, Rona Jeffrey A sold 3.90K, and ALEXANDER MARGARET A. bought 6.81K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OVID?: Yes. Rallies tracks OVID insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OVID research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OVID. It does not provide personalized investment advice.